Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Oct
19
Today In Oncology
Mocertatug Rezetecan (Mo-Rez) Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
National Academy of Medicine Elects 100 New Members for 2026
Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera
ASH Issues New Recommendations for the Management of Myelofibrosis
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo